Published in Curr Opin Gastroenterol on January 01, 2010
Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut (2012) 2.60
Small intestinal bacterial overgrowth syndrome. World J Gastroenterol (2010) 1.99
Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther (2010) 1.31
Clostridium difficile infection: new insights into management. Mayo Clin Proc (2012) 1.23
Clostridium difficile infection. Am J Med Sci (2010) 1.17
Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis (2013) 0.99
Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol (2011) 0.91
Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol (2011) 0.89
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol (2012) 0.87
Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplant (2016) 0.86
Breath Testing for Small Intestinal Bacterial Overgrowth: A Means to Enrich Rifaximin Responders in IBS Patients? Am J Gastroenterol (2016) 0.85
Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World J Gastroenterol (2014) 0.83
Clinical implications of enteroadherent Escherichia coli. Curr Gastroenterol Rep (2012) 0.83
Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. Gut Microbes (2015) 0.79
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem (2014) 0.79
Rifaximin therapy of irritable bowel syndrome. Clin Med Insights Gastroenterol (2012) 0.78
Rifaximin for the prevention of spontaneous bacterial peritonitis. World J Gastroenterol (2012) 0.77
Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis. Syst Rev (2012) 0.77
Gut microbiota and sirtuins in obesity-related inflammation and bowel dysfunction. J Transl Med (2011) 0.77
Ileocecal valve dysfunction in small intestinal bacterial overgrowth: a pilot study. World J Gastroenterol (2012) 0.76
Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol (2011) 0.76
Effects of rifaximin on bacterial translocation in thioacetamide-induced liver injury in rats. Inflammation (2012) 0.76
Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis. Integr Med (Encinitas) (2015) 0.76
Gut microbiome and liver disease. Transl Res (2016) 0.76
Novel prevention strategies for bacterial infections in cirrhosis. Expert Opin Pharmacother (2016) 0.75
Paediatric travel medicine: vaccines and medications. Br J Clin Pharmacol (2013) 0.75
Rifaximin for treatment of irritable bowel syndrome. Gastroenterol Hepatol (N Y) (2011) 0.75
The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood (2016) 0.75
Common changes in global gene expression induced by RNA polymerase inhibitors in Shigella flexneri. PLoS One (2012) 0.75
Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut Liver (2017) 0.75
The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol (2017) 0.75
Microbial influences in inflammatory bowel diseases. Gastroenterology (2008) 9.20
The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta (1967) 6.07
Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2003) 3.84
The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med (2006) 3.30
Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis (2007) 3.15
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut (2006) 2.82
A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med (2005) 2.58
Diverticular disease of the colon, a 20th century problem. Clin Gastroenterol (1975) 2.53
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother (2007) 2.43
Medical progress. Diverticular disease of the colon. N Engl J Med (1980) 2.26
Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol (2004) 1.98
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol (2003) 1.90
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother (2008) 1.84
Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol (2003) 1.77
Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship. Gastroenterology (1989) 1.71
A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol (2006) 1.67
In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother (2000) 1.65
Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis (2005) 1.53
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg (2006) 1.46
An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol (1996) 1.44
Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS. J Acquir Immune Defic Syndr (2008) 1.42
High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis (2009) 1.41
Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci (2007) 1.35
Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res (1994) 1.34
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther (2006) 1.33
Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci (2007) 1.29
Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci (1999) 1.29
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci (2007) 1.26
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther (1999) 1.24
Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment. Curr Treat Options Gastroenterol (2004) 1.24
Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology (1999) 1.22
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg (1996) 1.20
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis (2001) 1.19
Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther (2005) 1.19
High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2007) 1.17
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J (2005) 1.17
Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis (2001) 1.16
Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion (1998) 1.14
Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin (1993) 1.13
Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis (2002) 1.12
Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2000) 1.11
Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol (2009) 1.10
Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther (1995) 1.09
How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm Bowel Dis (1998) 1.09
An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin (2005) 1.08
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis (2006) 1.06
Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol (2008) 1.05
In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother (2001) 1.03
Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol (1991) 1.03
Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol (2007) 1.02
Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab (2007) 1.01
Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol (2007) 0.99
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother (2008) 0.99
Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scand J Gastroenterol (1993) 0.98
Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med (2009) 0.94
Expert review of the evidence base for self-therapy of travelers' diarrhea. J Travel Med (2009) 0.94
Systematic review: prevention of travellers' diarrhoea. Aliment Pharmacol Ther (2008) 0.94
Rifaximin for active ulcerative colitis. Inflamm Bowel Dis (2006) 0.93
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2007) 0.90
In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. Diagn Microbiol Infect Dis (2007) 0.90
Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol (2008) 0.88
Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol (2007) 0.88
Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. J Chemother (1999) 0.88
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother (2007) 0.88
The road to Rome. Gut (1999) 0.88
Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther (2007) 0.84
The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy (2007) 0.84
Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. J Travel Med (2010) 0.82
Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother (2007) 0.81
In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. J Antimicrob Chemother (2001) 0.81
Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series. Am J Gastroenterol (2008) 0.78
Amino acids in liver failure. Gastroenterology (1979) 0.77
Rifaximin, a rifamycin derivative for use in the treatment of intestinal bacterial infections in seriously disabled patients. J Int Med Res (1987) 0.76
Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection. Lancet Infect Dis (2005) 2.67
The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2006) 2.60
Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol (2004) 1.98
The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol (2011) 1.86
Rifaximin--a novel antimicrobial for enteric infections. J Infect (2005) 1.79
Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol (2003) 1.77
Noroviruses: The leading cause of gastroenteritis worldwide. Discov Med (2010) 1.73
Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis (2009) 1.70
Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis (2002) 1.64
Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. Ann Intern Med (2002) 1.61
A review of an emerging enteric pathogen: enteroaggregative Escherichia coli. J Med Microbiol (2006) 1.54
Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg (2009) 1.49
Persistent abdominal symptoms in US adults after short-term stay in Mexico. J Travel Med (2014) 1.47
The role of diet in the treatment of travelers' diarrhea: a pilot study. Clin Infect Dis (2004) 1.45
Seroepidemiology of norovirus-associated travelers' diarrhea. J Travel Med (2014) 1.43
Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol (2007) 1.41
Enteroaggregative Escherichia coli is a cause of acute diarrheal illness: a meta-analysis. Clin Infect Dis (2006) 1.38
The controversial and short-lived early use of rehydration therapy for cholera. Clin Infect Dis (2008) 1.38
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther (2010) 1.35
Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis (2003) 1.30
Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J Infect Dis (2002) 1.25
Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis (2006) 1.21
Epidemiology of travelers' diarrhea: details of a global survey. J Travel Med (2004) 1.21
Association of diarrheagenic Escherichia coli Pathotypes with infection and diarrhea among Mexican children and association of atypical Enteropathogenic E. coli with acute diarrhea. J Clin Microbiol (2008) 1.21
Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers. J Clin Microbiol (2002) 1.19
A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother (2011) 1.18
Enteroaggregative Escherichia coli: an emerging enteric pathogen. Am J Gastroenterol (2004) 1.18
Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico. J Infect Dis (2002) 1.15
Asymptomatic norovirus infection in Mexican children. J Clin Microbiol (2006) 1.13
Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol (2014) 1.12
Association of putative enteroaggregative Escherichia coli virulence genes and biofilm production in isolates from travelers to developing countries. J Clin Microbiol (2006) 1.09
A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infect Dis (2007) 1.09
Drug-resistant diarrheogenic Escherichia coli, Mexico. Emerg Infect Dis (2005) 1.08
A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol (2006) 1.06
Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol (2011) 1.05
Virulence characteristics and the molecular epidemiology of enteroaggregative Escherichia coli isolates from travellers to developing countries. J Med Microbiol (2007) 1.03
Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico. J Travel Med (2002) 1.03
Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. J Clin Microbiol (2005) 1.03
Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic Escherichia coli. Clin Diagn Lab Immunol (2004) 1.02
Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis (2012) 1.02
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother (2008) 0.99
Associations between mucosal innate and adaptive immune responses and resolution of diarrheal pathogen infections. Infect Immun (2009) 0.98
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther (2005) 0.97
Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother (2010) 0.97
Impact of vitamin A on selected gastrointestinal pathogen infections and associated diarrheal episodes among children in Mexico City, Mexico. J Infect Dis (2006) 0.97
The search for effective treatment of Clostridium difficile infection. N Engl J Med (2011) 0.95
Effect of vitamin A and zinc supplementation on gastrointestinal parasitic infections among Mexican children. Pediatrics (2007) 0.94
In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. Antimicrob Agents Chemother (2010) 0.93
The effect of vitamin A supplementation on the intestinal immune response in Mexican children is modified by pathogen infections and diarrhea. J Nutr (2006) 0.93
Influence of host interleukin-10 polymorphisms on development of traveler's diarrhea due to heat-labile enterotoxin-producing Escherichia coli in travelers from the United States who are visiting Mexico. Clin Vaccine Immunol (2008) 0.93
Enterotoxigenic Escherichia coli heat-labile toxin seroconversion in US travelers to Mexico. J Travel Med (2008) 0.92
The patient presenting with acute dysentery--a systematic review. J Infect (2012) 0.92
Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico. J Clin Microbiol (2010) 0.92
Toxin synthesis by Clostridium difficile is regulated through quorum signaling. MBio (2015) 0.91
Current and future developments in travelers' diarrhea therapy. Expert Rev Anti Infect Ther (2006) 0.91
Advances in defining etiology and new therapeutic approaches in acute diarrhea. J Infect (2007) 0.91
Patterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience. Clin Infect Dis (2011) 0.90
Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to Noroviruses. J Med Virol (2006) 0.90
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol (2004) 0.89
Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. J Travel Med (2007) 0.89
Noroviruses as a potential cause of protracted and lethal disease in immunocompromised patients. Clin Infect Dis (2009) 0.88
Enterotoxigenic Escherichia coli and diffusely adherent E. coli as likely causes of a proportion of pathogen-negative travelers' diarrhea--a PCR-based study. J Travel Med (2008) 0.85
Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin (2007) 0.85
Seroprevalence of the enteroaggregative Escherichia coli virulence factor dispersin among USA travellers to Cuernavaca, Mexico: a pilot study. J Med Microbiol (2008) 0.85
Single nucleotide polymorphisms in the promoter of the gene encoding the lipopolysaccharide receptor CD14 are associated with bacterial diarrhea in US and Canadian travelers to Mexico. Clin Infect Dis (2011) 0.85
A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol (2002) 0.84
Improvement in detection of enterotoxigenic Escherichia coli in patients with travelers' diarrhea by increasing the number of E. coli colonies tested. Am J Trop Med Hyg (2009) 0.84
Characterization of the human gut microbiome during travelers' diarrhea. Gut Microbes (2015) 0.84
Seasonality of diarrheagenic Escherichia coli pathotypes in the US students acquiring diarrhea in Mexico. J Travel Med (2011) 0.84
A hospital-based study of the clinical characteristics of Clostridium difficile infection in children. Pediatr Infect Dis J (2014) 0.83
Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis (2003) 0.82
Supplementation with vitamin A reduces watery diarrhoea and respiratory infections in Mexican children. Br J Nutr (2007) 0.82
Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. J Travel Med (2010) 0.82
Detection of enteroaggregative Escherichia coli with formalin-preserved HEp-2 cells. J Clin Microbiol (2002) 0.81
Vitamin A modifies the intestinal chemokine and cytokine responses to norovirus infection in Mexican children. J Nutr (2011) 0.81
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther (2010) 0.81
Epidemiology of cryptosporidiosis in North American travelers to Mexico. Am J Trop Med Hyg (2008) 0.81
Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol (2014) 0.81
Azithromycin for the self-treatment of traveler's diarrhea. Clin Infect Dis (2006) 0.80
Motility abnormalities in irritable bowel syndrome. Digestion (2014) 0.80
Enteroinvasive Escherichia coli severe dysentery complicated by rotavirus gastroenteritis. J Infect (2006) 0.79
Efficacy of a travelers' diarrhea vaccine system in travelers to India. J Travel Med (2013) 0.79
Vitamin A supplementation modifies the association between mucosal innate and adaptive immune responses and resolution of enteric pathogen infections. Am J Clin Nutr (2011) 0.78
Bile salt inhibition of host cell damage by Clostridium difficile toxins. PLoS One (2013) 0.78
Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci (2012) 0.77
United States male students who heavily consume alcohol in Mexico are at greater risk of travelers' diarrhea than their female counterparts. J Travel Med (2005) 0.77
Clostridium difficile-related death rates in Texas 1999-2005. J Infect (2009) 0.77
Development and accuracy of quantitative real-time polymerase chain reaction assays for detection and quantification of enterotoxigenic Escherichia coli (ETEC) heat labile and heat stable toxin genes in travelers' diarrhea samples. Am J Trop Med Hyg (2013) 0.77
Gender risk differences for surgical site infections among a primary coronary artery bypass graft surgery cohort: 1995-1998. Am J Infect Control (2006) 0.76
Relearning the importance of disease prevention among international travelers. Am J Gastroenterol (2007) 0.75
Pulsed-field gel electrophoresis for Salmonella infection surveillance, Texas, USA, 2007. Emerg Infect Dis (2010) 0.75
Coliform and Escherichia coli contamination of desserts served in public restaurants from Guadalajara, Mexico, and Houston, Texas. Am J Trop Med Hyg (2009) 0.75
Clostridium difficile: an emerging pathogen in children. Discov Med (2012) 0.75
Campylobacter jejuni is not an important pathogen as a cause of diarrhea in US travelers to Mexico. J Travel Med (2010) 0.75
Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol (2016) 0.75
Travelers' diarrhea: modern concepts and new developments. Curr Treat Options Gastroenterol (2006) 0.75
Pilot study of whole-blood gamma interferon response to the Vibrio cholerae toxin B subunit and resistance to enterotoxigenic Escherichia coli-associated diarrhea. Clin Vaccine Immunol (2010) 0.75
Unraveling the role of host endocytic proteins in pedestal formation during enteropathogenic Escherichia coli infection. J Infect Dis (2011) 0.75
Comment: Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin. Ann Pharmacother (2017) 0.75